Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Jazz Emerge 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Next Previous
X
Search
Trial Profile

Jazz Emerge 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EMERGE 402; Jazz Emerge 402; SCLC
  • Sponsors Jazz Pharmaceuticals Inc

    • Most Recent Events

    • 04 Jun 2024 Results (n=105 ) assessing updated safety data and HCRU, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Apr 2024 According to a Jazz Pharmaceuticals plc media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
    • 09 Apr 2024 Planned End Date changed from 1 Jan 2026 to 30 Jun 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top